LDK378 dihydrochlorideALK inhibitor CAS# 1380575-43-8 |
- LDK378
Catalog No.:BCC3691
CAS No.:1032900-25-6
- LDN193189 Hydrochloride
Catalog No.:BCC1695
CAS No.:1062368-62-0
- AP26113
Catalog No.:BCC1069
CAS No.:1197958-12-5
- SB525334
Catalog No.:BCC2531
CAS No.:356559-20-1
- TAE684 (NVP-TAE684)
Catalog No.:BCC3660
CAS No.:761439-42-3
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1380575-43-8 | SDF | Download SDF |
| PubChem ID | 67973512 | Appearance | Powder |
| Formula | C28H38Cl3N5O3S | M.Wt | 631.06 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Ceritinib dihydrochloride | ||
| Solubility | H2O : ≥ 170 mg/mL (269.39 mM); | ||
| Chemical Name | 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine;dihydrochloride | ||
| SMILES | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl.Cl.Cl | ||
| Standard InChIKey | WNCJOPLFICTLPT-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H36ClN5O3S.2ClH/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4;;/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34);2*1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | LDK378 2Hcl (Ceritinib) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
IC50 Value: 0.2 nM [1]
Target: ALK
in vitro: LDK378 shows great anti-proliferative activity in Ba/F3-NPM-ALK and Karpas290 cells with IC50 of 26.0 nM and 22.8 nM, compared with IC50 of 319.5 nM and 2477 nM in Ba/F3-Tel-InsR and Ba/F3-WT cells [1].
in vivo: LDK378 is designed to reduce the possibility of forming reactive metabolites and shows undetectable levels of glutathione (GSH) adducts (<1%) in liver microsomes. LDK378 has relatively good metabolic stability, with moderate CYP3A4 (Midazolam substrate) inhibition and hERG inhibition. LDK378 exhibits low plasma clearance in animals (mouse, rat, dog and monkey) compared to liver blood flow, with the oral bioavailability of above 55% in mouse, rat, dog and monkey. LDK378 induces a dose-dependent growth inhibition and tumor regression in the Karpas299 and H2228 rat xenograft models, with no body-weight loss. LDK378 shows no impact on insulin levels or plasma glucose utilization in the mouse upon chronic dosing up to 100 mg/kg [1]. References: | |||||
LDK378 dihydrochloride Dilution Calculator
LDK378 dihydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5846 mL | 7.9232 mL | 15.8464 mL | 31.6927 mL | 39.6159 mL |
| 5 mM | 0.3169 mL | 1.5846 mL | 3.1693 mL | 6.3385 mL | 7.9232 mL |
| 10 mM | 0.1585 mL | 0.7923 mL | 1.5846 mL | 3.1693 mL | 3.9616 mL |
| 50 mM | 0.0317 mL | 0.1585 mL | 0.3169 mL | 0.6339 mL | 0.7923 mL |
| 100 mM | 0.0158 mL | 0.0792 mL | 0.1585 mL | 0.3169 mL | 0.3962 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
LDK378 is a highly potent inhibitor of anaplastic lymphoma kinase (ALK), which is a receptor tyrosine kinase belonging to the superfamily of insulin receptor, with half maximal inhibitory concentration IC50 of 200 pM. LDK378 also exhibits modest to high inhibition against a panel of other kinases, in which only three kinases with IC50 below 100 nM includes IGF-1R (8 nM), InsR (7 nM) and STK22D (23 nM). In previous studies, LDK378 has been found to inhibit the proliferation of Ba/F3 cells transfected with the NPM-ALK fusion gene and Karpas 299 human non-Hodgkin’s Ki-positivr large cell lymphoma harboring the NPM-ALK fusion gene with IC50 of 22.8 nM and 26 nM.
References:
[1]Chen J, Jiang C, Wang S. LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J Med Chem. 2013 Jul 25;56(14):5673-4. doi: 10.1021/jm401005u. Epub 2013 Jul 9.
[2]Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26.
- 2-(4-Hydroxy-2-oxoindolin-3-yl)acetonitrile
Catalog No.:BCN1575
CAS No.:1380540-77-1
- YM 750
Catalog No.:BCC7542
CAS No.:138046-43-2
- EHop-016
Catalog No.:BCC5022
CAS No.:1380432-32-5
- KML 29
Catalog No.:BCC6312
CAS No.:1380424-42-9
- Valeriandoid B
Catalog No.:BCN6754
CAS No.:1380399-57-4
- EPZ004777 HCl
Catalog No.:BCC4550
CAS No.:1380316-03-9
- EPZ5676
Catalog No.:BCC2215
CAS No.:1380288-87-8
- KB SRC 4
Catalog No.:BCC6253
CAS No.:1380088-03-8
- BET bromodomain inhibitor
Catalog No.:BCC6426
CAS No.:1380087-89-7
- Decorticasine
Catalog No.:BCN2006
CAS No.:1380-03-6
- Limonene
Catalog No.:BCN3797
CAS No.:138-86-3
- Shikimic acid
Catalog No.:BCN6200
CAS No.:138-59-0
- G007-LK
Catalog No.:BCC6383
CAS No.:1380672-07-0
- Acetylanonamine
Catalog No.:BCN2140
CAS No.:138079-62-6
- (R,R)-THC
Catalog No.:BCC7224
CAS No.:138090-06-9
- Agomelatine
Catalog No.:BCN2165
CAS No.:138112-76-2
- 7-Methoxy-1-naphthylacetonitrile
Catalog No.:BCN2242
CAS No.:138113-08-3
- H-β-HoPhe-OH
Catalog No.:BCC3240
CAS No.:138165-77-2
- (RS)-(Tetrazol-5-yl)glycine
Catalog No.:BCC6599
CAS No.:138199-51-6
- ML 289
Catalog No.:BCC6343
CAS No.:1382481-79-9
- Stearyl glycyrrhetinate
Catalog No.:BCN8486
CAS No.:13832-70-7
- Hedycoronen A
Catalog No.:BCN7653
CAS No.:1383441-73-3
- CYM 9484
Catalog No.:BCC6238
CAS No.:1383478-94-1
- BD 1008 dihydrobromide
Catalog No.:BCC6674
CAS No.:138356-09-9
